Zero Candida Innovates Reporting Practices and Enhances Women's Health Solutions

Zero Candida Announces Significant Corporate Changes

Zero Candida, known as ZCT, is an exceptional Israeli FemTech start-up specializing in innovative medical devices aimed at improving women's health. Recent developments have led the company to adopt a semi-annual financial reporting system, allowing it to streamline its disclosure responsibilities in line with regulatory guidelines, thereby focusing more resources on revolutionary health technologies.

Transition to Semi-Annual Reporting

Effective May 25, 2026, Zero Candida will be implementing semi-annual financial reporting in accordance with Coordinated Blanket Order 51-933. This system exempts the company from filing interim financial reports and associated Management’s Discussion & Analysis (MDA) for its first and third quarters of the fiscal year. Specifically, the company will not release reports for the first quarter ending March 31, 2026, nor for the third quarter ending September 30, 2026. Instead, Zero Candida will ensure that audited annual financial statements are released within 120 days post fiscal year-end and six-month interim reports are provided within 60 days of June 30.

This change reinforces Zero Candida’s positioning as a venture issuer with annual revenues below $10 million, affirmatively showing its compliance with registration and reporting obligations crucial for maintaining credibility with investors.

Breakthrough Technology in Women's Health

Apart from restructuring its financial reporting, Zero Candida is making strides in its cutting-edge FemTech solutions. The company has developed a promising device that addresses Vulvo-Vaginal Candidiasis (VVC), a condition affecting approximately 75% of women globally. This innovative product is a smart, tampon-like device utilizing therapeutic light to eradicate Candida fungus efficiently with a success rate of 99.999% during point-of-care treatments.

The unique feature of Zero Candida’s device lies in its controlled blue light technology that targets and kills fungi quickly, without adverse side effects that conventional treatments might bring. This not only revolutionizes the treatment methodology for women but may also set new benchmarks in the FemTech industry.

Zero Candida aims to enhance access to its device, enabling hybrid medical services provided by gynecologists worldwide. This is particularly significant in regions where women have previously encountered barriers to treatment, such as in developing countries. The ZCT device is engineered to collect and transmit treatment data in real-time, allowing physicians to tailor treatment plans effectively amidst increasingly complex healthcare needs. This capability ensures seamless patient management and consulting through its embedded Wi-Fi chip and VoIP technology.

Commitment to Offering Non-Chemical Solutions

Another groundbreaking aspect of the Zero Candida device is its commitment to providing non-toxic treatments for women seeking healthier lifestyle choices. As demand grows for effective health solutions minimizing chemical exposure, this innovative approach resonates strongly with the wellness movement among modern women.

In conclusion, Zero Candida is not merely updating its corporate governance but is actively working towards transforming women's health technology. With a firm commitment to innovation and patient care, the company is set to lead a new chapter in FemTech that focuses on safety, accessibility, and comprehensive health solutions for women around the globe.

For more information about Zero Candida and its pioneering technologies, visit their website at Zero-Candida.com or follow them on social media @Zero-candida.